<DOC>
	<DOCNO>NCT01441661</DOCNO>
	<brief_summary>This non-interventional study include patient advance renal cell carcinoma treat Sunitinib alone combine systemic therapy . The aim trial increase knowledge usage , dosage , efficacy safety condition routine use Sunitinib .</brief_summary>
	<brief_title>Sunitinib Intake Conditions Treatment Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description>Because State Food Drug Administration ( SFDA ) exempt manufacturer conduct clinical trial Sunitinib China , overall efficacy safety data Sunitinib Chinese patient renal cell carcinoma deficiency . The investigator carry research project sufficient evidence , help clinician China make decision real daily practice .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologically confirm , unresectable advanced renal cell carcinoma ; Sunitinib firstline treatment alone combined therapy . History Grade 3/4 severe allergic reaction Sunitinib metabolite</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Sunitinib</keyword>
	<keyword>kidney disease</keyword>
	<keyword>urogenital neoplasm</keyword>
	<keyword>kidney cancer</keyword>
</DOC>